Introduction Little data is available on patients with advanced non-squamous NSCLC
treated with erlotinib specifically after failure of first-line pemetrexed-containing …

Lung cancer is the most common cancer diagnosis in the world and the leading cause of
cancer-related death. Despite considerable investment into drug development, to date, the …

Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …

Objective To explore the efficacy and safety of erlotinib monotherapy for advanced non-
small cell lung cancer (NSCLC). Methods Totally 50 patients with advanced NSCLC …

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase
inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib …

Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …

The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …

BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …

Background Combined inhibition of vascular, platelet-derived, and epidermal growth factor
receptor (EGFR) pathways may overcome refractoriness to single agents in platinum …